AbbVie announced positive late-breaking Phase 3 data for RINVOQ in non-segmental vitiligo, showing continued facial and total body repigmentation through week 76. The data also indicated enhanced repigmentation when RINVOQ was combined with phototherapy, suggesting a potential for improved treatment outcomes and market expansion for the drug.
AbbVie presented positive late-breaking Phase 3 data for its drug RINVOQ in treating non-segmental vitiligo. The filing highlights continued repigmentation through 76 weeks and improved results when combined with phototherapy, indicating strong efficacy. This is significant for AbbVie as it expands the potential market and indications for RINVOQ, a key growth driver for the company. For traders, this reinforces the drug's value and could lead to increased revenue projections, offering a positive long-term outlook for ABBV. The short-term impact might be moderate as this is an update on ongoing trials, but it de-risks future regulatory approvals and commercial success in this indication.